Literature DB >> 26648815

An updated review of Cucurbitacins and their biological and pharmacological activities.

Sun Ok Chung1, Yong Joo Kim1, Sang Un Park2.   

Abstract

Entities:  

Year:  2015        PMID: 26648815      PMCID: PMC4669946          DOI: 10.17179/excli2015-283

Source DB:  PubMed          Journal:  EXCLI J        ISSN: 1611-2156            Impact factor:   4.068


× No keyword cloud information.

Dear Editor,

Cucurbitacins (Cus) are a class of highly oxidized tetracyclic triterpenoids that confer a bitter taste to cucurbits such as cucumber, melon, watermelon, squash, and pumpkin. To date, a large number of Cus and Cu-derived compounds have been isolated from the Cucurbitaceae family and from other species of the plant (Alghasham, 2013[1]; Shang et al., 2014[2]). Cus have a range of biological and pharmacological activities that first attracted attention in the 1960s (Chen et al., 2012[3]). Cucurbitacin B (CuB) and Cucurbitacin E (CuE) have been particularly widely studied (Lan et al., 2013[4]). Recent reports have demonstrated that CuE has growth-inhibitory effects in the proliferation of many cancer cells such as bladder cancer, hepatocellular carcinoma, pancreatic cancer, breast cancer, and leukemia (Dong et al., 2010[5]; Sörensen et al., 2012[6]). CuB has been shown to have antimicrobial and anti-inflammatory activity. However, most reports on CuB focus on its anticancer activity. CuB inhibits the growth of human malignant cells, both in vitro and in vivo, and has been shown to be effective against breast cancer, head and neck squamous cell carcinoma, pancreatic cancer, hepatocellular carcinoma, osteosarcoma, and myeloid leukemia (Duangmano et al., 2010[7]; Kausar et al., 2013[8]; Guo et al., 2014[9]). Consequently, natural and semisynthetic Cus are proposed as a promising source for the development of new drugs for the prevention and treatment of various cancers. Here, we summarize key recent studies that have evaluated the biological and pharmacological activities of Cu and its derivatives (Table 1(Tab. 1)).
Table 1

Recent studies on Cus and their biological and pharmacological activities

References in Table 1: Zhang et al., 2014[10]; Jacquot et al., 2014[11]; Kong et al., 2014[12]; Guo et al., 2014[13]; Feng et al., 2014[14]; Hsu et al., 2014[15]; Gupta and Srivastava, 2014[16]; Gao et al., 2014[17]; Yuan et al., 2014[18]; Wang et al., 2014[19]; Ma et al., 2014[20]; Seo et al., 2014[21]; Kim et al., 2013[22]; Johnson et al., 2013[23]; Song et al., 2013[24]; Lan et al., 2013[4]; Hung et al., 2013[25]; Spear et al., 2013[26]; He et al., 2013[27]; Qiao et al., 2013[28]; Kausar et al., 2013[8]; Abbas et al., 2013[29]; Aribi et al., 2013[30]; Duangmano et al., 2012[31]; Zhang et al., 2012[32].

Acknowledgements

This research was supported by Agriculture, Food and Rural Affairs Research Center Support Program, Ministry of Agriculture, Food and Rural Affairs.
  32 in total

1.  Cucurbitacin IIa induces caspase-3-dependent apoptosis and enhances autophagy in lipopolysaccharide-stimulated RAW 264.7 macrophages.

Authors:  Jian He; Yao Wang; Li-hui Xu; Jing Qiao; Dong-yun Ouyang; Xian-hui He
Journal:  Int Immunopharmacol       Date:  2013-03-27       Impact factor: 4.932

2.  Cucurbitacin E, a tetracyclic triterpenes compound from Chinese medicine, inhibits tumor angiogenesis through VEGFR2-mediated Jak2-STAT3 signaling pathway.

Authors:  Yanmin Dong; Binbin Lu; Xiaoli Zhang; Jing Zhang; Li Lai; Dali Li; Yuanyuan Wu; Yajuan Song; Jian Luo; Xiufeng Pang; Zhengfang Yi; Mingyao Liu
Journal:  Carcinogenesis       Date:  2010-08-23       Impact factor: 4.944

3.  Growth inhibitory effect of Cucurbitacin E on breast cancer cells.

Authors:  Tian Lan; Linling Wang; Qian Xu; Weiguo Liu; Hongchuan Jin; Weimin Mao; Xian Wang; Xiaojia Wang
Journal:  Int J Clin Exp Pathol       Date:  2013-08-15

4.  Cucurbitacins - a promising target for cancer therapy.

Authors:  Abdullah A Alghasham
Journal:  Int J Health Sci (Qassim)       Date:  2013-01

5.  Natural compounds as potential treatments of NF2-deficient schwannoma and meningioma: cucurbitacin D and goyazensolide.

Authors:  Samuel A Spear; Sarah S Burns; Janet L Oblinger; Yulin Ren; Li Pan; A Douglas Kinghorn; D Bradley Welling; Long-Sheng Chang
Journal:  Otol Neurotol       Date:  2013-10       Impact factor: 2.311

6.  Cucurbitacin-D-induced CDK1 mRNA up-regulation causes proliferation arrest of a non-small cell lung carcinoma cell line (NSCLC-N6).

Authors:  Catherine Jacquot; Benedicte Rousseau; Delphine Carbonnelle; Ioanna Chinou; Marine Malleter; Christophe Tomasoni; Christos Roussakis
Journal:  Anticancer Res       Date:  2014-09       Impact factor: 2.480

7.  Antiproliferative effects of cucurbitacin B in breast cancer cells: down-regulation of the c-Myc/hTERT/telomerase pathway and obstruction of the cell cycle.

Authors:  Suwit Duangmano; Sumana Dakeng; Weena Jiratchariyakul; Apichart Suksamrarn; Duncan R Smith; Pimpicha Patmasiriwat
Journal:  Int J Mol Sci       Date:  2010-12-22       Impact factor: 5.923

8.  Cucurbitacin B induced ATM-mediated DNA damage causes G2/M cell cycle arrest in a ROS-dependent manner.

Authors:  Jiajie Guo; Guosheng Wu; Jiaolin Bao; Wenhui Hao; Jinjian Lu; Xiuping Chen
Journal:  PLoS One       Date:  2014-02-04       Impact factor: 3.240

9.  Cucurbitacin B inhibits human breast cancer cell proliferation through disruption of microtubule polymerization and nucleophosmin/B23 translocation.

Authors:  Suwit Duangmano; Phorntip Sae-Lim; Apichart Suksamrarn; Frederick E Domann; Pimpicha Patmasiriwat
Journal:  BMC Complement Altern Med       Date:  2012-10-12       Impact factor: 3.659

10.  Trichosanthes kirilowii Ethanol Extract and Cucurbitacin D Inhibit Cell Growth and Induce Apoptosis through Inhibition of STAT3 Activity in Breast Cancer Cells.

Authors:  Soon Re Kim; Hye Sook Seo; Han-Seok Choi; Sung-Gook Cho; Yong Kuk Kim; Eun Hee Hong; Yong Cheol Shin; Seong-Gyu Ko
Journal:  Evid Based Complement Alternat Med       Date:  2013-09-30       Impact factor: 2.629

View more
  6 in total

1.  Cytotoxic effects of natural and semisynthetic cucurbitacins on lung cancer cell line A549.

Authors:  Izabella Thaís Silva; Fabiana Cristina Geller; Lara Persich; Sabine Eva Dudek; Karen Luise Lang; Miguel Soriano Balparda Caro; Fernando Javier Durán; Eloir Paulo Schenkel; Stephan Ludwig; Cláudia Maria Oliveira Simões
Journal:  Invest New Drugs       Date:  2016-01-16       Impact factor: 3.850

2.  Antibacterial and antioxidant activities of extracts and isolated compounds from the roots extract of Cucumis prophetarum and in silico study on DNA gyrase and human peroxiredoxin 5.

Authors:  Wario Galma; Milkyas Endale; Emebet Getaneh; Rajalakshmanan Eswaramoorthy; Temesgen Assefa; Yadessa Melaku
Journal:  BMC Chem       Date:  2021-05-06

3.  Metabolomic analysis of the occurrence of bitter fruits on grafted oriental melon plants.

Authors:  Shuangshuang Zhang; Lanchun Nie; Wensheng Zhao; Qiang Cui; Jiahao Wang; Yaqian Duan; Chang Ge
Journal:  PLoS One       Date:  2019-10-10       Impact factor: 3.240

4.  Isolation of anticancer constituents from Cucumis prophetarum var. prophetarum through bioassay-guided fractionation.

Authors:  Abdulrhman Alsayari; Lucas Kopel; Mahmoud Salama Ahmed; Hesham S M Soliman; Sivakumar Annadurai; Fathi T Halaweish
Journal:  BMC Complement Altern Med       Date:  2018-10-09       Impact factor: 3.659

5.  Effect of a multimodality Ayurveda treatment in a case of Visphota kushta.

Authors:  I V Aiswarya; K Parameswaran Namboothiri; P V Anandaraman
Journal:  J Ayurveda Integr Med       Date:  2019-01-17

6.  The Mechanisms of Cucurbitacin E as a Neuroprotective and Memory-Enhancing Agent in a Cerebral Hypoperfusion Rat Model: Attenuation of Oxidative Stress, Inflammation, and Excitotoxicity.

Authors:  Zhiyong Liu; Manish Kumar; Sushma Devi; Atul Kabra
Journal:  Front Pharmacol       Date:  2021-12-10       Impact factor: 5.810

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.